A Single-arm, Open-label, Phase II Study to Evaluate Clinical Efficacy, Safety and Pharmacokinetics of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination with Chemotherapy (Carboplatin-Etoposide) in Previously Untreated Japanese Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Evaluate Clinical Efficacy, Safety and Pharmacokinetics of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination with Chemotherapy (Carboplatin-Etoposide) in Previously Untreated Japanese Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Start Date31 Mar 2025

Sponsor / Collaborator

Shanghai Henlius Biotech, Inc.

NCT06692491

/ Not yet recruitingPhase 2IIT

A Phase II Clinical Study on Precision Treatment of Rare Tumours in China Guided by Patient-Derived Tumor Organoids (PDO) and Next-Generation Sequencing (NGS)

The objective of this Phase II, open-label, multicenter, non-randomised controlled clinical trial is to guide precision treatment for patients with rare tumours based on Patient-Derived Organoids/Next-Generation Sequencing drug screening.

Start Date01 Jan 2025

Sponsor / Collaborator

Peking University Shenzhen Hospital

NCT06716619

/ Not yet recruitingPhase 1

A Phase I Clinical Trial of the Safety and Tolerability of Tumor-Associated Lymph Node T-Cell Injection (TAL-T) in Subjects With Advanced Malignant Solid Tumors

A Phase I clinical trial of the safety and tolerability of tumor-associated lymph node T cell injection in patients with advanced malignant solid tumors, including but not limited to melanoma, head and neck tumors, cervical cancer, and non-small cell lung cancer.

Start Date20 Dec 2024

Sponsor / Collaborator

Guangzhou Fan'en Biotechnology Co., Ltd.

[+1]

100 Clinical Results associated with Serplulimab

100 Translational Medicine associated with Serplulimab

100 Patents (Medical) associated with Serplulimab

432

Literatures (Medical) associated with Serplulimab

01 Feb 2025·INTERNATIONAL IMMUNOPHARMACOLOGY

Deep analysis of the trials and major challenges in the first-line treatment for patients with extensive-stage small cell lung cancer

Review

Author: Yin, Xiaoyan ; Wu, Peizhu ; Zhuang, Lulu ; Gao, Ran ; Meng, Xiangjiao

The median overall survival (OS) is approximately 10 months when chemotherapy alone is the first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). The approval of the two PD-L1 inhibitors, atezolizumab and durvalumab, marked the beginning of the immunotherapy era for ES-SCLC. Serplulimab, as the first PD-1 inhibitor to achieve success in the first-line treatment of ES-SCLC, has not only demonstrated significant improvements in patient survival outcomes but also ushered in a new era for PD-1 inhibitors in the treatment of ES-SCLC. Recently, antiangiogenic agents with chemo-immunotherapy have achieved breakthroughs in first-line ES-SCLC treatment. Improving the clinical benefits of individualized treatment for patients with ES-SCLC remains challenging. Challenges include identifying biomarkers for targeted therapy, exploring new treatments, developing new medicines, and classifying SCLC molecular subtypes. This review provides an in-depth analysis of research on first-line ES-SCLC treatment. Additionally, it discusses advances in ES-SCLC treatment.

01 Jan 2025·BIOMEDICINE & PHARMACOTHERAPY

Combined treatment of small cell lung cancer using radiotherapy and immunotherapy: Challenges and updates

Review

Author: Cao, Zhumin ; Tian, Ke ; Wang, Bin ; Jiang, Jinxiu ; Deng, Kai

Currently, chemotherapy remains the standard first- and second-line treatment for small cell lung cancer (SCLC). Research concerning immunotherapy has brought about a remarkable development in the treatment pattern of SCLC. Atirizumab, duvalizumab, atezolizumab, and serplulimab can significantly improve the clinical outcomes of SCLC. Given the rapidly evolving concept that combining immunotherapy with radiotherapy can increase therapeutic effectiveness, clinicians are devoted to further improving local tumor control by integrating immunotherapy with radiotherapy. This paper reviews the research progress in this field to date and explores ways to further enhance the efficacy of this combination therapy. We first discussed that immunotherapy combined with radiotherapy can improve the abscopal effect, progression-free survival, and overall survival rates of SCLC patients. Then, the biomarkers related to the radiation immune microenvironment, such as programmed death ligand-1 (PD-L1), tumor mutational burden (TMB), and the immune function of patients were discussed. Next, we explored the occurrence and underlying mechanisms of immune resistance during radiotherapy implementation. Finally, we clarified that the emerging trend of low-dose radiotherapy help overcome the inhibitory signals that limit T-cell infiltration in the tumor matrix. In summary, considering the rapid development of this field, these combined therapy strategies may have unlimited potential to further improve the efficacy of radiotherapy combined with immunotherapy for patients.

31 Dec 2024·Human vaccines & immunotherapeutics

Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report

Article

Author: Chen, Jialu ; Yang, Jiayao ; Zhang, Yao ; Shou, Liumei ; Shu, Qijin ; Shao, Tianyu

Immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic option for large cell neuroendocrine carcinoma (LCNEC). However, various studies have suggested a potential risk of hyperprogressive disease (HPD) in patients receiving ICI, which might be associated with gene alterations. Here, this is the first report on an unknown primary LCNEC patient who had achieved a long-term response from ICI treatment (atezolizumab), but developed HPD after tumor progression due to receiving another ICI agent (serplulimab). The mutation region of FAT4, SMARCA4, CYLD, CTNNB1, and KIT was altered prior to serplulimab treatment compared to before atezolizumab treatment. This case suggested a potential association between these mutated genes and HPD. Patients with the aforementioned genes should caution when selecting ICI treatment. These findings required further confirmation in a larger study cohort.

News (Medical) associated with Serplulimab

11 Feb 2025

·pipelinereview.com

The first patient has been dosed in a phase 2 clinical study of HLX43 for injection (antibody-drug conjugate targeting PD-L1 with novel DNA topoisomerase I inhibitor) for the treatment of recurrent/metastatic esophageal squamous cell carcinoma (ESCC)

HONGKONG, China I February 10, 2025 I A. INTRODUCTION This announcement is made by Shanghai Henlius Biotech, Inc. (the “Company”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business development of the Company. The board of directors (the “Board”) of the Company is pleased to announce that, recently, the first patient has been dosed in a phase 2 clinical study of HLX43 for injection (antibody-drug conjugate targeting PD-L1 with novel DNA topoisomerase I inhibitor) (“HLX43”) in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC) in mainland China (excluding Hong Kong, Macau and Taiwan regions, the same as below). After the conditions are met, the Company also plans to initiate phase 2 clinical trials for the treatment of potential indications such as cervical cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, head and neck squamous cell carcinoma and non-small cell lung cancer. B. CLINICAL TRIAL DESIGN AND OBJECTIVES This study is a phase 2 clinical trial designed to evaluate the efficacy and safety of different doses of HLX43 in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC) who have failed or are intolerant to first-line standard treatment. Eligible subjects will receive HLX43 every 3 weeks (Q3W). The primary objective of this study is to assess the clinical efficacy of HLX43 in recurrent/metastatic ESCC. Secondary objectives include evaluating safety and tolerability, pharmacokinetic characteristics and immunogenicity, and potential predictive biomarkers. C. ABOUT HLX43 HLX43 is an antibody-drug conjugate (ADC) targeting PD-L1 developed by the Company through conjugating the novel DNA topoisomerase I inhibitor payload – peptide linker, licensed-in from MediLink Therapeutics (Suzhou) Co., Ltd. in November 2022, with antibody targeting PD-L1 independently developed by the Company, which is designed for the treatment of advance/metastatic solid tumours. In October 2023, application for phase 1 clinical trial of HLX43 for the treatment of advanced/metastatic solid tumours was approved by the National Medical Products Administration (“NMPA”), and the first patient has been dosed in such trial in November 2023 in mainland China. In November 2023, application for phase 1 clinical trial of HLX43 for the treatment of advanced/metastatic solid tumours was approved by the United States Food and Drug Administration (FDA). In December 2024, application for phase 1b/2 clinical trial of HLX43 for the monotherapy or combination therapy of advanced/metastatic solid tumours was approved by the NMPA. In January 2025, the application for phase 1b/2 clinical trial of HLX43 in combination with HANSIZHUANG (serplulimab injection) for the D. MARKET CONDITION As at the date of this announcement, no antibody-drug conjugate targeting PD-L1 has been approved for marketing globally. SOURCE: Henlius Biotech

Phase 2Phase 1ADCINDDrug Approval

06 Feb 2025

·www.prnewswire.com

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY| NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's") for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection. Dr. Reddy's will gain exclusive rights to commercialize both subcutaneous and intravenous formulation of HLX15 in a total of 43 countries and regions, comprising 42 European countries and regions and the United States (U.S.). Under the terms of the agreement, Henlius will be responsible for development, manufacturing and commercial supply, and may receive up to a total of $131.6 million, including a $33 million upfront payment and additional milestone payments. In addition, Henlius is eligible to receive royalties on annual net sales of the product. Dr. Reddy's is a global pharmaceutical company, operating in over 75 countries across the globe. Through a partnership with Dr. Reddy's, Henlius aims to boost the growth and reach of its products in the European and U.S. markets, providing local patients with enhanced treatment options. "This collaboration with Dr. Reddy's on HLX15 is a significant step in our response to global health needs and improving access to advanced biologics," said Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius. "Dr. Reddy's has a long-standing dedication to oncology, driven by the purpose that 'Good Health Can't Wait', and is committed to timely access to affordable and high-quality medicines, which complement Henlius' focus on addressing unmet medical needs in research and development. We are confident that this partnership will enhance the global market competitiveness of both organizations in oncology treatment, ultimately allowing us to reach and support more patients around the world." "We are pleased to join hands with Dr. Reddy's, signifying a pivotal moment in Henlius' journey to expand our global partner network," said Ping Cao, Chief Business Development Officer and SVP of Henlius, "Henlius' robust product development capabilities in biosimilars, along with its advanced manufacturing and quality systems that meet global standards, paired with Dr. Reddy's vast experience and resources in the global commercialization of biosimilars, positions this collaboration to effectively harness the strengths of both organizations. Together, we aim to deliver more high-quality and affordable treatment options to the U.S. and European markets." Erez Israeli, Chief Executive Officer of Dr. Reddy's, said: "We are pleased to collaborate with Henlius to make this daratumumab biosimilar available to patients in the U.S., and Europe. Over the years, we have created a portfolio of biosimilar products that are being marketed in several emerging markets. This latest collaboration with Henlius further progresses our regulated markets journey in biosimilars. Additionally, oncology has been a top focus therapy area for us. We look forward to leveraging our strong commercial capabilities in these markets to ensure patients receive access to best-in-class therapies and affordable treatment options." About HLX15 HLX15 is a fully human anti-CD38 IgG1κ monoclonal antibody independently developed by Henlius, and is a biosimilar candidate to Darzalex® & Darzalex Faspro®* which are indicated for the treatment of multiple myeloma. In accordance with the biosimilar guidelines of NMPA, EMA, and USFDA, HLX15 is being developed following the principles of stepwise development. HLX15 and reference daratumumab are considered comparable based on analytical similarity assessment and pre-clinical studies. In June 2024, the Phase 1 clinical study (NCT05679258) of HLX15 was successfully completed, meeting its primary endpoint. The findings indicate that HLX15 had similar pharmacokinetic characteristics, as well as comparable safety and immunogenicity profiles to the US-, EU-, and CN-sourced daratumumab. Comparative efficacy studies are currently underway. *Darzalex® & Darzalex Faspro® are registered trademarks of Johnson & Johnson. About Dr. Reddy's Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: . About Henlius Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 6 products have been launched in China, 4 have been approved for marketing in overseas markets, and 4 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP. Henlius has pro-actively built a diversified and high-quality product pipeline covering over 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company's launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG (serplulimab, trade name: Hetronifly® in the EU), the world's first anti-PD-1 mAb for the first-line treatment of SCLC, and HANNAIJIA (neratinib). What's more, Henlius has conducted over 30 clinical studies for 16 products, expanding its presence in major markets as well as emerging markets. SOURCE Henlius WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

License out/inPhase 1Drug Approval

06 Feb 2025

·www.prnewswire.com

Accord Healthcare: Hetronifly® (Serplulimab) receives Marketing Authorisation from the European Commission (EC), for the treatment of Extensive-Stage Small Cell Lung Cancer (ES- SCLC)

Hetronifly is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC (in combination with carboplatin and etoposide). Hetronifly is the only anti-PD-1 mAb approved in Europe for the treatment of ES-SCLC and is already approved in China, and several Southeast Asian countries. In December 2022, Hetronifly received orphan drug designation from the EC for the treatment of SCLC, which was renewed in 2025. The European Society for Medical Oncology (ESMO) scores serplulimab 4 out of 5 on their magnitude of clinical benefit scale (MCBS) in ES-SCLC. LONDON, Feb. 6, 2025 /PRNewswire/ -- Accord Healthcare Limited (Accord) announced today that the anti-PD-1 mAb, serplulimab, marketed as Hetronifly® in Europe, has been officially approved by the European Commission (EC) for use in combination with carboplatin and etoposide as a first-line treatment for ES-SCLC. This makes it the first anti-PD-1 monoclonal antibody to be approved in Europe for the treatment of ES-SCLC. Serplulimab was originated by Henlius Biotech. In 2023, Henlius entered into a collaboration with Intas Pharmaceuticals, granting Intas exclusive rights to develop and commercialise serplulimab in over 50 countries across Europe and India. This latest approval covers all 27 EU member states as well as the European Economic Area countries, including Norway, Iceland, and Liechtenstein. Commercialisation in Europe will be led by Accord. In December 2022, serplulimab received orphan drug designation from the EC for the treatment of SCLC, this was recently reviewed by the committee and renewed. ESMO scores serplulimab 4 out of 5 on their magnitude of clinical benefit scale (MCBS) in ES-SCLC. Welcoming the news Paul Tredwell, Executive Vice-President, EMENA, Accord Healthcare said: "At Accord, we are committed to transforming the lives of patients, and this approval of Hetronifly allows us to provide a much-needed new treatment option for patients with extensive stage small cell lung cancer. It also underlines our dedication to building our speciality business and driving innovation in oncology; a therapy area we have huge heritage in. "With our partners at Henlius, we can now have confidence that some of the most unwell lung cancer patients can benefit, giving them more precious time with their families and loved ones. Together, we will continue to collaborate to expand our pipeline of innovative medicines, further underlying our commitment to developing speciality medicines to provide a real difference to patients' lives in Europe and beyond." About Serplulimab Serplulimab (recombinant humanised anti-PD-1 monoclonal antibody injection)) is the first anti-PD-1 mAb for the first-line treatment of SCLC and has been approved in China and several SEA countries. Serplulimab has been approved by the National Medicinal Products Administration (NMPA) in China for the treatment of squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC) and non-squamous non-small cell lung cancer (nsNSCLC). Serplulimab was granted orphan drug designations by the FDA and the EC for the treatment of SCLC, and its bridging head-to-head trial in the United States to compare serplulimab to standard of care atezolizumab (anti-PD-L1 mAb) for the first-line treatment of ES-SCLC is well under way. The results of 4 pivotal trials of serplulimab were published in the Journal of the American Medical Association (JAMA), Nature Medicine, Cancer Cell and British Journal of Cancer, respectively. Furthermore, serplulimab was respectively recommended by the CSCO Guidelines for Small Cell Lung Cancer, the CSCO Guidelines for Non-Small Cell Lung Cancer, the CSCO Guidelines for Esophageal Cancer, the CSCO Clinical Practice Guidelines on Immune Checkpoint Inhibitor, the China Guidelines for Radiotherapy of Esophageal Cancer, and other definitive guides, providing valuable references for clinical diagnosis and treatment of tumours. About Lung Cancer Lung cancer is the most common cancer worldwide in terms of incidence and mortality. According to GLOBOCAN 2022, there were over 2.48 million new cases of lung cancer globally in 2022, accounting for 12.4% of all new cancer cases.1 Small cell lung cancer (SCLC), which accounts for 15% to 20% of all lung cancers, is characterised by high malignancy, early metastasis, rapid progression, and poor prognosis. Among SCLC patients, approximately 30% to 40% are diagnosed at a limited stage, while the remaining cases are in extensive stage. Within Europe, the prevalence of SCLC ranges from 1 to 5 per 10,000 people.2 References Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834 Dingemans AC, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2021;32(7):839-853. doi:10.1016/j.annonc.2021.03.207 Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalOrphan DrugLicense out/inImmunotherapy

100 Deals associated with Serplulimab

External Link

KEGG	Wiki	ATC	Drug Bank
-	Serplulimab	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Non-squamous non-small cell lung cancer	CN	Shanghai Henlius Biopharmaceuticals Co. , Ltd.	01 Dec 2024
Esophageal Squamous Cell Carcinoma	CN	Shanghai Henlius Biopharmaceuticals Co. , Ltd.	19 Sep 2023
Extensive stage Small Cell Lung Cancer	CN	Shanghai Henlius Biopharmaceuticals Co. , Ltd.	16 Jan 2023
Squamous non-small cell lung cancer	CN	Shanghai Henlius Biopharmaceuticals Co. , Ltd.	25 Oct 2022
Advanced gastric carcinoma	CN	Shanghai Henlius Biopharmaceuticals Co. , Ltd.	22 Mar 2022
Colorectal Cancer	CN	Shanghai Henlius Biopharmaceuticals Co. , Ltd.	22 Mar 2022
Microsatellite Instability-high Solid Tumors	CN	Shanghai Henlius Biopharmaceuticals Co. , Ltd.	22 Mar 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Esophageal Carcinoma	NDA/BLA	CN	Shanghai Henlius Biopharmaceuticals Co. , Ltd.	26 Aug 2022
Microsatellite Instability cancer	NDA/BLA	CN	Shanghai Henlius Biotech, Inc.	23 Apr 2021
Stomach Cancer	Phase 3	CN	Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.	30 Jan 2023
Advanced Cervical Carcinoma	Phase 3	CN	Shanghai Henlius Biotech, Inc.	30 Sep 2022
Small cell lung cancer limited stage	Phase 3	US	Shanghai Henlius Biotech, Inc.	17 May 2022
Small cell lung cancer limited stage	Phase 3	CN	Shanghai Henlius Biotech, Inc.	17 May 2022
Small cell lung cancer limited stage	Phase 3	AT	Shanghai Henlius Biotech, Inc.	17 May 2022
Small cell lung cancer limited stage	Phase 3	CZ	Shanghai Henlius Biotech, Inc.	17 May 2022
Small cell lung cancer limited stage	Phase 3	DE	Shanghai Henlius Biotech, Inc.	17 May 2022
Small cell lung cancer limited stage	Phase 3	GR	Shanghai Henlius Biotech, Inc.	17 May 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04547166 (ASCO_GI2025)	Phase 2/3	Metastatic Colorectal Carcinoma First line PD-L1 expression level \| microsatellite stable (MSS) status	114	Serplulimab + Bevacizumab + XELOX	xgsjgacatf(xbumilodvo) = hmupwhdqoi gtobhdtgwx (bohnmvfpjj, 10.7 - NA) View more	Positive	23 Jan 2025
				Placebo + Bevacizumab + XELOX	xgsjgacatf(xbumilodvo) = tqxtqboeqk gtobhdtgwx (bohnmvfpjj, NA) View more
NCT05659251 (ESMO_IO2024) Manual	Phase 2	Esophageal Squamous Cell Carcinoma Neoadjuvant	48	Serplulimab + Chemotherapy	kystsmnrqf(ofiynmnozh) = phodoktkmo mxwhdhjgnj (vpvgkkoxom ) View more	Positive	12 Dec 2024
ESMO_IO2024 Manual	Not Applicable	Extensive stage Small Cell Lung Cancer Third line \| Second line \| First line	40	Serplulimab + Chemotherapy + Anlotinib (first-line)	dyisxinsqc(iohpasrxxn) = vomsklgjno hyxzsbzlzg (bjfukdsihu, 15.6 - NR) View more	Positive	12 Dec 2024
NEWS Manual	Phase 2	Renal Cell Carcinoma First line	16	斯鲁利单抗+呋喹替尼	fkrrqdhlgy(tnchrkamqd) = pryzlngehb wfbocoxdcb (ljfriuutyg ) View more	Positive	09 Dec 2024
ASTRUM-004R (ESMO_ASIA2024) Manual	Not Applicable	Squamous non-small cell lung cancer First line	100	Serplulimab plus Paclitaxel	ybqibiiflf(cqjuhozfma) = dwlspeofnr idmsprpdih (siejvytrzc ) View more	Positive	07 Dec 2024
				Serplulimab plus Nab-paclitaxel	ybqibiiflf(cqjuhozfma) = chmcwehzth idmsprpdih (siejvytrzc ) View more
NCT04033354 (ASTRUM-004, NEWS) Manual	Phase 3	Squamous non-small cell lung cancer First line	359	斯鲁利单抗+化疗	uebqljjvhh(ucxomrwzmx) = qmlezotgav dncssenomw (zeiorptgph ) View more	Positive	29 Sep 2024
				安慰剂+化疗	uebqljjvhh(ucxomrwzmx) = qeyorlcsdu dncssenomw (zeiorptgph ) View more
NCT04033354 (ASTRUM-004, ESMO2024) Manual	Phase 3	Squamous non-small cell lung cancer First line	309	Serplulimab plus chemotherapy	poibtpcykb(bghhaxqobb) = lhfbxlhwai spsrurjzpa (wburxwmijb ) View more	Positive	15 Sep 2024
				Placebo plus chemotherapy	poibtpcykb(bghhaxqobb) = jmgjgzufjj spsrurjzpa (wburxwmijb ) View more
NCT05443646 (ASTRUM-LC01, ESMO2024) Manual	Phase 2	Small Cell Lung Cancer Consolidation	55	Serplulimab 300mg	qsbeshngjq(wbncwlfkkc) = pgdmeqptgu gddigxqxrz (ahgloqgetj, 60.1 - 85.8) View more	Positive	14 Sep 2024
ESMO2024	Not Applicable	Extensive stage Small Cell Lung Cancer	-	Serplulimab	fuaevepdnk(qyqrvlwjki) = hasgofasui agzllkbznn (eaooinmaho ) View more	-	14 Sep 2024
				Chemotherapy	fuaevepdnk(qyqrvlwjki) = cihwviweng agzllkbznn (eaooinmaho ) View more
NCT04063163 (ASTRUM-005, WCLC2024) Manual	Phase 3	Extensive stage Small Cell Lung Cancer First line	538	Serplulimab combined with chemotherapy	mdszfvvmqw(odurwlxhuh) = rvynybpnth qlqxwleybm (fktsbgnveo ) View more	Positive	08 Sep 2024
				Serplulimab combined with chemotherapy (the Asian)	mdszfvvmqw(odurwlxhuh) = ohbvgfwflf qlqxwleybm (fktsbgnveo ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis